ALSUntangled #74: Withania Somnifera (Ashwagandha). Amyotroph Lateral Scler Frontotemporal Degener 2024 Feb 06:1-4
Date
02/06/2024Pubmed ID
38318860DOI
10.1080/21678421.2024.2311721Scopus ID
2-s2.0-85184427525 (requires institutional sign-in at Scopus site)Abstract
ALSUntangled reviews alternative and off-label treatments on behalf of people with ALS (PALS) who ask about them. Here, we review withania somnifera (WS) commonly known as ashwagandha or winter cherry. WS has plausible mechanisms for slowing ALS progression because of its effects on inflammation, oxidative stress, autophagy, mitochondrial function, and apoptosis. Preclinical trials demonstrate that WS slows disease progression in multiple different animal models of ALS. Of the five individuals we found who described using WS for their ALS, two individuals reported moderate benefit while none reported experiencing any significant side effects. There is currently one clinical trial using WS to treat PALS; the results are not yet published. There are no serious side effects associated with WS and the associated cost of this treatment is low. Based on the above information, WS appears to us to be a good candidate for future ALS trials.
